everbliss-10mg-everolimus-tablet-1000x1000

EVEROLIMUS (EVERBLISS) Tablet

$1,018.00

Everolimus Everbliss 5/10MG Tablet represents a significant therapeutic advance in the management of cancer and autoimmune diseases, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging conditions. With careful monitoring, patient education, and access to treatment, Everolimus holds promise in reshaping the landscape of oncology and immunosuppression and providing hope for those affected by these diseases.

Sku:

N/A

Tag:

EVEROLIMUS EVERBLISS

Description

Everolimus Everbliss 5/10MG Tablet stands as a pioneering medication in the realm of oncology and immunosuppression, offering a potent treatment option for individuals grappling with various types of cancer and certain autoimmune diseases. With its active ingredient everolimus, this oral medication represents a significant advancement in the management of these complex conditions, providing renewed hope and improved outcomes for patients facing these challenging diagnoses.

Key Features:

mTOR Inhibitor: Everolimus is a potent inhibitor of the mammalian target of rapamycin (mTOR), a key signaling pathway involved in cell growth, proliferation, and angiogenesis. By blocking mTOR signaling, everolimus effectively inhibits the growth and spread of cancer cells, as well as the activity of immune cells implicated in autoimmune diseases.
Treatment of Cancer: Everolimus Everbliss Tablet is indicated for the treatment of various types of cancer, including advanced renal cell carcinoma (RCC), hormone receptor-positive, HER2-negative breast cancer, pancreatic neuroendocrine tumors (pNET), and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). It offers a valuable therapeutic option for individuals with these malignancies, extending survival and improving quality of life.
Immunosuppressive Therapy: In addition to its anti-cancer properties, Everolimus is also utilized as an immunosuppressive agent in certain autoimmune diseases and following organ transplantation to prevent rejection. It helps to suppress the immune system’s response and reduce inflammation associated with these conditions.
Multiple Strengths: Available in tablet form with strengths of 5mg and 10mg, Everolimus Everbliss Tablet allows for personalized dosing tailored to individual patient needs and treatment plans, facilitating optimized therapeutic outcomes.
Oral Administration: Administered orally once daily, Everolimus Everbliss Tablet is typically taken at the same time each day, with or without food. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
Efficacy: Clinical trials have demonstrated the efficacy of everolimus in prolonging progression-free survival and overall survival in patients with advanced RCC, breast cancer, pNET, and SEGA associated with TSC. It has shown superiority over placebo and other treatments, both as a monotherapy and in combination with other agents.
Side Effects: Common side effects of Everolimus may include stomatitis (mouth sores), rash, diarrhea, fatigue, and peripheral edema. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring and reporting of any concerning symptoms to their healthcare provider.
Consultation with Healthcare Provider: Treatment with Everolimus Everbliss Tablet should be initiated and monitored by a qualified oncologist, nephrologist, or transplant specialist experienced in the use of mTOR inhibitors. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.
Access and Affordability: Efforts should be made to ensure access to Everolimus for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Everolimus Everbliss 5/10MG Tablet represents a significant therapeutic advance in the management of cancer and autoimmune diseases, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging conditions. With careful monitoring, patient education, and access to treatment, Everolimus holds promise in reshaping the landscape of oncology and immunosuppression and providing hope for those affected by these diseases.